P2RY12

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, P2RY12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated P2RY12 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher P2RY12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated P2RY12 expression acts as an unfavorable survival marker.

SCLC, CESC, and UCEC are the cancer types where P2RY12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SCLCOSMedianAll0.0550.708<.00112view →
CESCDFSMedianIII,IV0.2400.726.0156view →
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

P2RY12–SCLC (OS)

Kaplan–Meier survival curve for P2RY12 mutant vs wild-type samples in SCLC.

Open the SCLC breakdown →

Exploration